Related Experiment Video
Updated: Jan 8, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
New-Onset Atrial Fibrillation Potentially Associated With Tirzepatide: A Case Report
Akhtar Purvez1,2, Mohd Mirza3, Mudhasir Bashir4
1Clinical Research, Momentum Medical Research, Charlottesville, USA.
Tirzepatide, a GIP/GLP-1 receptor agonist, may rarely cause atrial fibrillation (AF) in patients without prior heart issues. Discontinuation resolved the AF, emphasizing monitoring for cardiac events with incretin therapies.
Area of Science:
- Cardiology
- Endocrinology
- Pharmacology
Background:
- Tirzepatide, a dual GIP and GLP-1 receptor agonist, is widely used for type 2 diabetes and obesity.
- While generally beneficial for cardiometabolic health, rare adverse cardiac events have been reported.
Related Concept Videos
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
Acute Coronary Syndrome III: Diagnostic Studies
Acute Coronary Syndrome I: Introduction
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
Atherosclerosis III: Management
Dysrhythmias II: Classification of Tachyarrhythmias

